Clinical Trials Logo
  1. Home
  2. Lipoprotein Lipase Deficiency
  3. NCT02656095

Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment

Lipoprotein Lipase Deficiency Clinical Trial

Official title:
Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment

Clinical Trial Summary

This study plans to learn more about measuring Lipoprotein lipase (LPL) activity in humans. LPL is an enzyme in the breakdown of certain types of fats into smaller parts. Lipoprotein lipase deficiency (LPLD) is a very rare genetic disorder in which lipoprotein enzyme is no longer functional. This can cause conditions known as high triglycerides in the blood and inflammation of the pancreas.

Investigational medications to treat LPLD are currently being developed. In order to see if these medications are effective, it is necessary to be able to accurately measure LPL activity in humans.

LPL activity has been successfully measured in animal models after giving heparin. Heparin is a blood thinner which is approved by the FDA. It is originally used to prevent blood clots. This study will administer heparin to healthy adults through intravenous infusion (IV). Blood samples will be collected before and after the infusion to test LDL levels.

The purpose of this study is to develop a cheap, more reliable standard for assessment of LPLD in patients

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02656095
Study type Observational
Source University of Colorado, Denver
Contact
Status Completed
Phase
Start date March 2016
Completion date March 1, 2018
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01448577 - Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies N/A
Completed NCT03293810 - Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients
Recruiting NCT04227678 - Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency N/A
Completed NCT02658175 - The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome Phase 3
Completed NCT03360747 - Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) Phase 2
Withdrawn NCT03198897 - Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)